Healthcare

IDTechEx will be hosting a free webinar on Tuesday 21 November titled Medical Biosensors for Monitoring and Diagnostics.

Raghu Das, CEO and Chris Clare, Event Director, IDTechEx tells you what to expect at the upcoming IDTechEx Show! held at the Santa Clara Convention Center, November 15-16 2017.

What is a point-of-care device? Dr David Pugh et al. discuss how biosensors are changing the ways that diseases are diagnosed.

Connected healthcare is a transformative socio-technological model for healthcare management and delivery that leverages a range of technology innovations available today in order to provide optimized, flexible, targeted healthcare services.

Multifunctional probes are extremely useful for research purposes, as they allow the recording of neural activity simultaneously alongside stimulation via drug administration or light (as is the case with optogenetics).

European Commission's Horizon 2020 SME (small-medium sized enterprises) Instrument recently announced Sensars Neuroprosthetics as a Phase 1 recipient for funding of their SENSY technology. Phase 1 recipients receive €50000 in funding for 6 months to execute a feasibility study and draft a 10-page business proposal. This is intended to bring the technology from the idea to concept stage. There are currently 2813 participants, 2750 projects coordinated, and 1094,87M€ allocated to the Horizon 2020 SME Instrument.

IDTechEx's free, expert led webinars provide up-to-date insights on the latest emerging technology trends. You can now access these at a time that suits you, for up to one month.

The new IDTechEx Research report, Neuroprosthetics 2018-2028: Technologies, Forecasts, Players, covers the competitive landscape for cochlear implants, retinal implants and neuroprosthetic limbs, a market that is expected to reach $18 billion by 2028.

The University of Florida performs its first retinal implant with the Argus II by Second Sight. The Argus II is an epiretinal implant consisting of an inner electrode array placed in the eye where it can stimulate the remaining cells in the retina, effectively taking the place of the rod and cone cells that have died off due to degenerative retinal diseases like retinitis pigmetosa.

Doxorubicin, originally daunorubicin, is the result of a simultaneous discovery event in the 1950's between researchers in France and Italy. The molecule, a well-known anti-cancer drug used for a variety of indications ranging from acute lymphocytic leukemia to breast cancer, was approved for use in the United States in 1974.